Biogen Idec bought thre CNS programsfrom Neurimmune for $32.5 M upfront plus future payments up to $395 M in future milestones. In acquiring the 3 candidate drugs targeted to the neurotoxic proteins alpha-synuclein, tau, and TDP-43, Biogen acquires potential therapeutics aimed at Alzheimer's, ALS (Lou Gehrig's disease) and Parkinson's.
"Biogen Idec is committed to becoming the global leader in the development of innovative therapies for neurodegenerative diseases," said Alfred Sandrock, senior vice president, neurology research and development, Biogen. See Fierce Biotech.
Posted by Bruce Lehr December 21st 2010.